US Patent 4,870,086: Ropivacaine Patent Scope, Expiration, Litigation and Generic Entry Analysis

US Patent 4,870,086 covers ropivacaine hydrochloride monohydrate, the S-enantiomer of 1-propyl-2',6'-pipecoloxylidide, at the compound, purity, manufacturing-process and local-anesthetic method-of-use levels. The patent issued on September 26, 1989, and its 17-year US patent term expired on September 26, 2006. It no longer blocks manufacture, sale or use of ropivacaine in the United States. The covered product is the active ingredient in AstraZeneca's Naropin injection.

What drug does US Patent 4,870,086 protect?

The patent protects ropivacaine hydrochloride monohydrate, also known as:

Ropivacaine HCl monohydrate
(S)-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate
Ropivacaine hydrochloride
CAS Registry No. 132112-35-7 for the hydrochloride monohydrate form

Ropivacaine is a long-acting amide local anesthetic. The claimed molecule is the S-enantiomer. The corresponding R-enantiomer is not the claimed active compound.

Item	Patent-related information
US patent	US 4,870,086
Patent holder at issuance	Astra Läkemedel AB
Technology	Optically active N-substituted 2,6-pipecoloxylidides
Active ingredient	Ropivacaine
Covered salt	Hydrochloride
Covered solid form	Monohydrate
Issue date	September 26, 1989
US patent term	17 years from issue under the pre-URAA regime
Expiration date	September 26, 2006
FDA product	Naropin
NDA	019533
FDA approval	1996
Current blocking status	Expired

The patent is directed to a specific stereoisomer and hydrate rather than to every pipecoloxylidide local anesthetic. Its coverage is materially narrower than a genus patent covering all N-substituted 2,6-pipecoloxylidides.

How do the six claims divide the patent scope?

The six claims fall into four legal categories: product claims, purity claims, process claims and a method-of-use claim.

Claims	Claim category	Principal limitation
1	Product	Ropivacaine hydrochloride monohydrate
2	Product and purity	Compound is substantially optically pure
3	Product and purity	Less than 0.5% by weight of the R-enantiomer
4	Manufacturing process	Water-acetone crystallization under specified conditions
5	Narrow process	Specific water and acetone quantities
6	Method of use	Local anesthesia in mammals, including humans

Claim 1: ropivacaine hydrochloride monohydrate

Claim 1 is the broadest product claim. It requires all of the following:

The S-enantiomer of 1-propyl-2',6'-pipecoloxylidide.
The hydrochloride salt.
The monohydrate form.

A product containing the racemate would not satisfy the claim because the claim is limited to the S-enantiomer. A product containing the free base would not satisfy the claim because the hydrochloride salt is required. A different solid-state form, such as an anhydrous hydrochloride or another hydrate, would raise a claim-construction issue because claim 1 expressly identifies the monohydrate.

The claim does not expressly include the less-than-0.5% R-enantiomer limitation. That threshold appears in dependent claim 3.

Claim 2: substantially optically pure material

Claim 2 adds the requirement that the compound be substantially optically pure. The phrase is qualitative and would ordinarily be interpreted in light of the patent specification and technical practice at the relevant time.

Claim 2 is narrower than claim 1 because it adds an optical-purity limitation. A commercial process producing high-purity S-ropivacaine would likely be evaluated against both claim 2 and the more objective threshold in claim 3.

Claim 3: less than 0.5% of the R-enantiomer

Claim 3 provides the clearest quantitative purity limitation. It requires less than 0.5% by weight of the corresponding R-enantiomer.

This limitation is important in generic-product analysis because enantiomeric purity can be measured by chiral chromatography. A product with 0.50% or more of the R-enantiomer would not meet the literal numerical limitation of claim 3, assuming the measurement method and claim interpretation use the same basis.

Claim 3 does not eliminate the requirements inherited from claim 1. The product must still be:

The S-enantiomer;
In hydrochloride form; and
In monohydrate form.

Claims 4 and 5: crystallization process

Claim 4 covers a particular process for preparing the substantially optically pure monohydrate. The required steps are:

Dissolving S-ropivacaine hydrochloride in water.
Using water in an amount equal to 1 to 3 times the weight of the starting compound.
Adding acetone at 5 to 15 times the volume of water.
Using acetone at a temperature between 45 degrees Celsius and its boiling point.
Isolating the monohydrate.

Claim 5 narrows claim 4 to a preferred operating point:

Water volume equal to the weight of the ropivacaine hydrochloride.
Acetone volume equal to 10 times the water volume.

A process that omits one required limitation of claim 4 may avoid literal infringement of that process claim. Examples include using a solvent other than acetone, using acetone below 45 degrees Celsius, operating outside the specified solvent ratios, or recovering a different solid form. Equivalents analysis could still be relevant under historical infringement law, but the patent's expiration eliminates any current US enforcement risk.

Claim 6: local-anesthetic use

Claim 6 covers administering the compound of claim 1 to mammals, including humans, in an anesthetizing amount to induce local anesthesia.

The claim is not limited to a particular:

Dose;
Concentration;
Route of administration;
Injection site;
Surgical procedure;
Duration of anesthesia; or
Patient population.

Because claim 6 depends on claim 1, the administered compound must be ropivacaine hydrochloride monohydrate as claimed. The claim is not a broad claim to all uses of ropivacaine in every formulation independent of the claimed compound.

When did US Patent 4,870,086 expire?

US Patent 4,870,086 expired on September 26, 2006.

The patent issued before the Uruguay Round Agreements Act changed the US patent term from 17 years from grant to 20 years from the earliest effective nonprovisional filing date. For this patent, the pre-URAA term applied. The expiration date is therefore calculated from the issue date rather than from the priority or filing date.

The expiration has several consequences:

The compound claims are no longer enforceable.
The process claims are no longer enforceable.
The method-of-use claim is no longer enforceable.
A generic manufacturer does not need a license from the patent owner to practice the claimed chemistry.
A Paragraph IV challenge to this patent no longer creates a 30-month stay or prospective market exclusion.

What was the Orange Book status of ropivacaine?

The FDA Orange Book historically listed US 4,870,086 for Naropin, the reference product containing ropivacaine hydrochloride injection. The patent listing related to the active ingredient and its claimed form rather than to a separate device or delivery system.

FDA and Orange Book issue	Assessment
Reference product	Naropin
NDA holder	AstraZeneca group
Active ingredient	Ropivacaine hydrochloride
Dosage form	Injection
Regulatory pathway for generics	ANDA
Listed US patent	US 4,870,086
Patent status	Expired
Current 30-month stay risk	None from this patent
Biosimilar pathway	Not applicable

Ropivacaine is a chemically synthesized small molecule. Generic applicants use the ANDA pathway, not the abbreviated biosimilar pathway under section 351(k) of the Public Health Service Act.

What generic entry risks exist for ropivacaine?

The principal generic-entry risk is no longer patent infringement. It is commercial and regulatory execution.

A generic applicant must address:

Pharmaceutical equivalence to the reference product;
Bioequivalence or the applicable waiver standard;
Sterility assurance;
Container-closure integrity;
Stability;
Particulate control;
Labeling conformity; and
Manufacturing-site compliance.

Ropivacaine injection is generally supplied in multiple concentrations, including 0.2%, 0.5% and 0.75% presentations. Concentration-specific regulatory filings may create separate commercial launch opportunities even though the core active-ingredient patent has expired.

The relevant generic launch scenarios are:

Scenario	Patent effect	Commercial implication
Generic ropivacaine HCl injection	No blocking effect from US 4,870,086	Price competition against Naropin
Different concentration	No core patent barrier	Hospital formulary and procurement competition
Alternative container or presentation	No core patent barrier	Potential differentiation through packaging and supply
Alternative manufacturing process	May avoid expired process claims	Process freedom is commercially useful, not legally necessary
New method of use	Could implicate later patents if valid	Requires separate patent review

Which companies are challenging ropivacaine exclusivity?

No current Paragraph IV challenge against US 4,870,086 is legally operative because the patent expired in 2006.

Public ANDA activity involving ropivacaine has been driven by generic injectable manufacturers rather than by a continuing challenge to an enforceable compound patent. Potential market participants have included large hospital-injection suppliers and specialty generic manufacturers, but the identity and timing of individual ANDA applicants should be taken from current FDA approval records rather than inferred from the expired patent.

The commercial contest is therefore a post-exclusivity generic market. It is not a live patent-certification contest comparable to a product with an unexpired Orange Book patent.

What formulation patents protect ropivacaine products?

US 4,870,086 is not a broad formulation patent. It does not claim:

A particular vial or ampoule;
A specific injectable concentration;
A preservative system;
A container;
A prefilled syringe;
A continuous-infusion device;
A liposomal formulation; or
A polymeric depot system.

The patent claims the monohydrate compound and a process for producing it. A later patent could have covered a formulation, delivery system or specialized use, but such rights would have to be assessed separately by jurisdiction, claim scope and expiration date.

For standard ropivacaine hydrochloride injection, the primary historical patent barrier was US 4,870,086. Its expiration removed the core compound-level barrier.

How strong was the patent estate for ropivacaine?

The estate was technically strong during its term because it combined several claim types:

A direct product claim;
An optical-purity claim;
A quantitative enantiomer limit;
A solid-form limitation;
A manufacturing-process claim; and
A local-anesthesia method claim.

This structure gave the owner multiple infringement theories against a product containing the specified S-enantiomer hydrochloride monohydrate. The product claim was the most commercially important because it could reach the finished active ingredient regardless of the manufacturing route.

The estate had a narrow chemical perimeter. It did not cover all local anesthetics or every ropivacaine-related composition. Its value depended on the commercial importance of the specific S-enantiomer and on the absence of a commercially practical alternative solid form or active stereoisomer.

After September 26, 2006, the estate had no remaining US exclusionary value under the patent.

What patent litigation and licensing issues affect ropivacaine?

US 4,870,086 no longer supports an infringement action against a current US manufacturer or seller. A historical infringement dispute could remain relevant for damages incurred before expiration, subject to the applicable limitations period and procedural record, but the patent cannot provide a current injunction or future market block.

The patent record does not establish a continuing US license requirement for generic ropivacaine. Commercial rights to Naropin were associated with AstraZeneca and its predecessor Astra entities, while generic manufacturers could enter after patent expiration without taking a license under this patent.

No biosimilar litigation is relevant because ropivacaine is a small-molecule drug. Any current dispute would more likely involve manufacturing quality, product liability, procurement contracts, regulatory compliance or later patents rather than US 4,870,086.

How does ropivacaine compare with bupivacaine?

Issue	Ropivacaine	Bupivacaine
Chemical class	Amide local anesthetic	Amide local anesthetic
Key stereochemistry	S-enantiomer	Commonly marketed as racemate; levobupivacaine is the S-enantiomer
Historical brand	Naropin	Marcaine and others
US 4,870,086 coverage	Ropivacaine HCl monohydrate	Does not cover bupivacaine
Generic status	Mature generic market	Mature generic market
Biosimilar relevance	None	None
Main patent risk today	Later formulation or use patents	Later formulation or use patents

US 4,870,086 should not be treated as a patent on the entire long-acting amide local-anesthetic class. Its scope is limited to the identified ropivacaine stereoisomer, salt and hydrate.

Key Takeaways

US 4,870,086 covers ropivacaine hydrochloride monohydrate.
Claim 1 is the core product claim.
Claims 2 and 3 address optical purity, with claim 3 requiring less than 0.5% of the R-enantiomer.
Claims 4 and 5 cover a water-acetone crystallization process.
Claim 6 covers use of the compound for local anesthesia.
The patent expired on September 26, 2006.
It no longer creates an Orange Book-based market stay or a current Paragraph IV risk.
Ropivacaine is a small molecule and is regulated through the ANDA pathway, not the biosimilar pathway.
Current generic risk is commercial and regulatory rather than based on this expired patent.
Later formulation, delivery-system or method-of-use patents would require separate analysis.

FAQs About US Patent 4,870,086 and Ropivacaine

Does US Patent 4,870,086 cover racemic ropivacaine?

No. The claims are directed to the S-enantiomer, (S)-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate. A racemic product is not literally the claimed S-enantiomer product.

Can a generic company manufacture ropivacaine without a license today?

Yes, US 4,870,086 expired on September 26, 2006. A separate unexpired patent, regulatory exclusivity right or contractual restriction could change the analysis for a particular product, but this patent alone does not require a license.

Is ropivacaine subject to biosimilar competition?

No. Ropivacaine is a chemically synthesized small molecule. Generic versions are submitted through the ANDA pathway.

Does the patent cover ropivacaine liposomal formulations?

No. The issued claims cover the specified compound, monohydrate, crystallization process and local-anesthetic use. They do not expressly claim liposomal delivery or another specialized formulation platform.

What was the most valuable claim in US Patent 4,870,086?

Claim 1 was the most commercially significant because it directly covered the active ropivacaine hydrochloride monohydrate product. The process and method claims provided supplementary protection but were narrower and dependent on specific technical or use limitations.

References

Astra Läkemedel AB. (1989). United States Patent No. 4,870,086: (S)-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (1996). Naropin (ropivacaine hydrochloride) injection prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Code, 35 U.S.C. §§ 154, 156, 271 and 282.
United States Code, 21 U.S.C. § 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	8600017	Jan 03, 1986

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0239710	⤷ Start Trial	96C0042	Belgium	⤷ Start Trial
European Patent Office	0239710	⤷ Start Trial	SPC/GB96/051	United Kingdom	⤷ Start Trial
European Patent Office	0239710	⤷ Start Trial	C960005	Netherlands	⤷ Start Trial
Argentina	242561	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,870,086

Summary for Patent: 4,870,086